Edition:
United Kingdom

miRagen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

4.68USD
15 Oct 2018
Change (% chg)

$0.18 (+4.00%)
Prev Close
$4.50
Open
$4.57
Day's High
$4.73
Day's Low
$4.57
Volume
13,113
Avg. Vol
42,132
52-wk High
$10.68
52-wk Low
$4.40

Chart for

About

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product... (more)

Overall

Beta: 1.97
Market Cap(Mil.): $202.81
Shares Outstanding(Mil.): 21.48
Dividend: --
Yield (%): --

Financials

  MGEN.OQ Industry Sector
P/E (TTM): -- 85.91 32.75
EPS (TTM): -11.08 -- --
ROI: -87.08 1.70 14.60
ROE: -90.87 3.17 16.33

BRIEF-Miragen Therapeutics Reports Q1 Loss Per Share $0.18

* MIRAGEN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Miragen Announces Interim Data From Phase 1 Trial Of Cobomarsen In Mycosis Fungoides

* MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES

08 May 2018

BRIEF-Miragen Therapeutics Announces New Data Showing Administration Of MRG-110 Improved Tissue Perfusion And Wound Healing

* MIRAGEN THERAPEUTICS ANNOUNCES NEW DATA SHOWING ADMINISTRATION OF MRG-110 IMPROVED TISSUE PERFUSION AND WOUND HEALING IN LATE STAGE PRECLINICAL STUDIES

27 Apr 2018

Earnings vs. Estimates